Patents Assigned to Revivicor, Inc.
-
Publication number: 20240353409Abstract: The present disclosure provides novel serology methods for detecting viremic or latent zoonotic viral infections, such as porcine cytomegalovirus (PCMV) or Porcine lymphotropic herpesvirus (PLHV) infections, in a subject at any stage of development. More specifically, the present disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in biological fluids of a subject suspected of being infected with PCMV or PLHV.Type: ApplicationFiled: April 12, 2024Publication date: October 24, 2024Applicant: Revivicor, Inc.Inventor: Kasinath Venkata Kuravi
-
Publication number: 20230255185Abstract: The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.Type: ApplicationFiled: September 19, 2022Publication date: August 17, 2023Applicant: Revivicor, Inc.Inventors: Maria Kokkinaki, Kasinath V. Kuravi
-
Publication number: 20220257829Abstract: Disclosed are compositions derived from non-primate mammals having reduced expression of alpha 1,3 gal and their use in food products, food additives, cosmetic products, cosmetic additives, medical products, medical devices and products used in research and production of therapeutics. The compositions and methods disclosed are particularly useful to subjects diagnosed with ?-Gal Syndrome (AGS).Type: ApplicationFiled: October 10, 2019Publication date: August 18, 2022Applicant: Revivicor, Inc.Inventors: John Bianchi, David Ayares, Anneke Walters, Amy Dandro
-
Publication number: 20220211018Abstract: The present disclosure is directed to transgenic animals (e.g., transgenic porcine animals) comprising multiple genetic modifications that advantageously render these animals suitable donors for xenotransplanation. The present disclosure extends to organs, organ fragments, tissues and cells derived from these animals and their therapeutic use. The present disclosure further extends to methods of making such animals. In certain embodiments, the transgenic animals (e.g., transgenic porcine animals) have reduced expression of the growth hormone receptor (GHR) gene or have impaired function of the GHR protein.Type: ApplicationFiled: November 19, 2021Publication date: July 7, 2022Applicant: Revivicor, Inc.Inventors: Martine ROTHBLATT, David AYARES, Willard EYESTONE
-
GENETICALLY MODIFIED PIGS FOR XENOTRANSPLANTATION OF VASCULARIZED XENOGRAFTS AND DERIVATIVES THEREOF
Publication number: 20220072200Abstract: The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.Type: ApplicationFiled: November 22, 2021Publication date: March 10, 2022Applicant: Revivicor, Inc.Inventor: David AYARES -
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
Patent number: 11179496Abstract: The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.Type: GrantFiled: August 13, 2013Date of Patent: November 23, 2021Assignee: Revivicor, Inc.Inventor: David Ayares -
Patent number: 11172658Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.Type: GrantFiled: February 26, 2018Date of Patent: November 16, 2021Assignee: Revivicor, Inc.Inventors: Carol J. Phelps, David L. Ayares
-
Patent number: 11085054Abstract: The present invention provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which lack expression of functional endogenous immunoglobulin loci. The present invention also provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which express xenogenous, such as human, immunoglobulin loci. The present invention further provides ungulate, such as porcine genomic DNA sequence of porcine heavy and light chain immunogobulins. Such animals, tissues, organs and cells can be used in research and medical therapy. In addition, methods are provided to prepare such animals, organs, tissues, and cells.Type: GrantFiled: March 4, 2019Date of Patent: August 10, 2021Assignee: Revivicor, Inc.Inventors: Kevin Wells, David Ayares
-
Patent number: 10912863Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.Type: GrantFiled: October 24, 2018Date of Patent: February 9, 2021Assignee: Revivicor, Inc.Inventors: David Ayares, Paul Rohricht
-
Patent number: 10793873Abstract: The invention provides cells and animals, as well as methods of producing cells and animals, that express at least one interfering RNA molecule to regulate the expression of a specific gene or family of genes. The invention further provides novel iRNA molecules, as well as DNA templates for producing iRNA molecules.Type: GrantFiled: November 22, 2004Date of Patent: October 6, 2020Assignee: Revivicor, Inc.Inventor: Kevin Wells
-
Patent number: 10383317Abstract: The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided.Type: GrantFiled: May 5, 2016Date of Patent: August 20, 2019Assignee: Revivicor, Inc.Inventor: David L. Ayares
-
Patent number: 10300112Abstract: The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing the CTLA4-Ig for use in xenotransplantation, and nucleic acid constructs and vectors useful therein.Type: GrantFiled: May 17, 2012Date of Patent: May 28, 2019Assignee: Revivicor, Inc.Inventor: David Lee Ayares
-
Patent number: 10149461Abstract: Porcine animals, tissue and organs as well as cells and cell lines derived from such animals are provided that lack functional endogenous immunoglobulin loci and are deficient in immunoglobulin expression and B-cells. These animals are useful as model systems for research and for development of new pharmaceutical and biological agents. In addition, methods are provided to prepare such animals.Type: GrantFiled: March 23, 2015Date of Patent: December 11, 2018Assignee: Revivicor, Inc.Inventors: David L. Ayares, Michael Mendicino, Kevin Wells, Amy S. Dandro
-
Patent number: 10130737Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.Type: GrantFiled: August 1, 2014Date of Patent: November 20, 2018Assignee: Revivicor, Inc.Inventors: David Ayares, Paul Rohricht
-
Patent number: 9585374Abstract: The present invention provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which lack expression of functional endogenous immunoglobulin loci. The present invention also provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which express xenogenous, such as human, immunoglobulin loci. The present invention further provides ungulate, such as porcine genomic DNA sequence of porcine heavy and light chain immunogobulins. Such animals, tissues, organs and cells can be used in research and medical therapy. In addition, methods are provided to prepare such animals, organs, tissues, and cells.Type: GrantFiled: April 30, 2009Date of Patent: March 7, 2017Assignee: Revivicor, Inc.Inventors: Kevin Wells, David Ayares
-
Patent number: 9339519Abstract: The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (?GT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided.Type: GrantFiled: August 16, 2010Date of Patent: May 17, 2016Assignee: Revivicor, Inc.Inventor: David Ayares
-
Publication number: 20150182664Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.Type: ApplicationFiled: August 1, 2014Publication date: July 2, 2015Applicant: Revivicor, Inc.Inventors: David Ayares, Paul Rohricht
-
Patent number: 8106251Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.Type: GrantFiled: March 17, 2005Date of Patent: January 31, 2012Assignee: Revivicor, Inc.Inventors: David Ayares, Paul Rohricht
-
Patent number: 7795493Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.Type: GrantFiled: August 21, 2003Date of Patent: September 14, 2010Assignee: Revivicor, Inc.Inventors: Carol J. Phelps, David L. Ayares
-
Publication number: 20060147432Abstract: It has been found that dendritic cells can be prepared which cannot mature. These cells can provide signal 1 to T cells but cannot provide co-stimulatory signal 2. T cells which are stimulated by the permanently immature dendritic cells therefore anergise, so the dendritic cells are tolerogenic rather than immunogenic. The cells are generally CD40?ve, CD80?ve and CD86?ve, and remain so when stimulated by inflammatory mediators such as lipopolysaccharide. The cells can be prepared conveniently by the culturing adherent embryonic stem cells in the presence of GM-CSF.Type: ApplicationFiled: February 24, 2006Publication date: July 6, 2006Applicant: Revivicor, Inc.Inventors: Marilyn Moore, Andrew Leishman, Donald Innes